Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Donald Bobo, Jr. sold 11,340 shares of the firm's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the completion of the transaction, the vice president owned 21,266 shares of the company's stock, valued at approximately $1,827,387.38. This represents a 34.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Edwards Lifesciences Price Performance
Edwards Lifesciences stock opened at $87.27 on Tuesday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The firm has a market capitalization of $50.69 billion, a PE ratio of 47.69, a P/E/G ratio of 2.26 and a beta of 0.93. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The firm's 50-day simple moving average is $82.75 and its 200 day simple moving average is $81.34.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analysts' expectations of $1.54 billion. During the same period last year, the business earned $0.59 earnings per share. The company's revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of EW. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company's stock worth $10,719,000 after purchasing an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company's stock valued at $6,706,000 after acquiring an additional 10,078 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in shares of Edwards Lifesciences in the second quarter worth $300,000. Atlantic Union Bankshares Corp increased its position in Edwards Lifesciences by 2,240.9% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company's stock worth $925,000 after purchasing an additional 11,384 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp grew its stake in shares of Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company's stock valued at $3,481,000 after buying an additional 21,950 shares in the last quarter. Institutional investors own 79.46% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the company. Evercore restated an "outperform" rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. BTIG Research restated a "buy" rating and set a $103.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the stock a "buy" rating in a research report on Tuesday, January 20th. Finally, Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a "hold" rating in a report on Wednesday, December 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $96.14.
Check Out Our Latest Analysis on EW
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
